OM:VITRBiotechs
Vitrolife (OM:VITR) Valuation After Fourth Quarter Loss And Sharp Full Year Setback
Vitrolife (OM:VITR) is back in focus after reporting fourth quarter and full year 2025 results, with sales of SEK 891 million for the quarter and a net loss of SEK 5,314 million.
See our latest analysis for Vitrolife.
Despite a 4.36% 1 day share price gain to SEK89.7 after the earnings release, Vitrolife’s 30 day share price return of 32.61% and 1 year total shareholder return of 56.22% indicate pressure has been building for some time as investors reassess the business after the large...